Sculptra, the first proven regenerative biostimulator, will provide new options for patients in China who are looking for innovative treatments to correct mid-facial volume loss and/or contour deficiencies1-7
Sculptra is the only regenerative biostimulator supported by over 25 years of clinical evidence and safety while providing natural-looking results through to two years7-10
Galderma's journey is marked by continuous innovation and expansion, and with this new launch, products from across Galderma’s Injectable Aesthetics portfolio are now available in China, demonstrating its commitment to meeting the needs of even more patients and healthcare professionals
ZUG, Switzerland--(BUSINESS WIRE)--Galderma today announced the launch of Sculptra, the first proven regenerative biostimulator with a unique poly-L-lactic acid (PLLA-SCA™) formulation, in China.1-7,11-14 This follows Sculptra’s approval by China’s National Medical Products Administration for correcting mid-facial volume loss and/or contour deficiencies last year. Sculptra – which works with the body’s natural processes to achieve healthier, radiant skin and a more youthful appearance – will now be available in China, where growth of aesthetics has outpaced the global market in the past decade.15-18 This launch is indicative of Galderma’s commitment to expanding its unparalleled aesthetics portfolio into new geographies, in order to meet the needs of even more patients and healthcare professionals.
|
“Sculptra has a unique and rich history spanning over 25 years, and its launch in China signals the start of another chapter in its incredible journey. Patients and healthcare professionals in China will now have access to a premium product, backed by decades of clinical evidence, which can help them achieve their varied aesthetic needs by offering long-lasting and natural-looking results.”
BALDO SCASSELLATI SFORZOLINI, M.D., PH.D. GLOBAL HEAD OF R&D GALDERMA
|
|
